Effects of Semisupervised Exercise Training on Health Outcomes in People With Lung or Head and Neck Cancer: Protocol for a Randomized Controlled Trial.

ECOG ENDT Eastern Cooperative Oncology Group HRQoL QoL RCT aerobic exercise cancer treatment drug therapy ear nose throat ear, nose, and throat exercise head and neck neoplasms head cancer lung cancer lung neoplasms muscle strength neck cancer neoplasm oncology outpatient physical activity pulmonary quality of life radiotherapy

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
24 May 2023
Historique:
received: 23 12 2022
accepted: 21 03 2023
revised: 21 03 2023
medline: 24 5 2023
pubmed: 24 5 2023
entrez: 24 5 2023
Statut: epublish

Résumé

Lung or head and neck cancers are known for their high prevalence and mortality rates. Chemotherapy and radiotherapy are usually recommended as cancer treatment for these malignancies; however, they can negatively impact both the physical and mental status of patients. Hence, it is reasonable to consider resistance and aerobic exercise training to prevent these negative health outcomes. Further, several factors prevent patients from attending outpatient exercise training programs, and, therefore, a semisupervised home-based exercise training program may be seen as a well-accepted alternative. The aim of this study will be to investigate the effects of a semisupervised home-based exercise training program on physical performance, body composition, and self-reported outcomes; changes in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival in people with primary lung or head and neck cancer. Participants will be randomly allocated to the training group (TG) or control group (CG). The TG will undergo semisupervised home-based resistance and aerobic exercise training throughout their cancer treatment. The resistance training will be performed using elastic bands (TheraBand) twice a week. The aerobic training (ie, brisk walk) will be performed for at least 20 minutes per day outdoors. The equipment and tools used during the training sessions will be provided. This intervention will start the week before treatment commencement, will be performed throughout the duration of the treatment, and will continue for 2 weeks after treatment completion. The CG will undergo usual care (ie, cancer treatment with no formal exercise prescription). Assessments will take place 2 weeks before the beginning of the usual cancer treatment and 2 weeks after treatment completion. The measures of physical function (peripheral muscle strength, functional exercise capacity, and physical activity), body composition, and self-reported outcomes (symptoms of anxiety and depression, health-related quality of life, and symptoms related to the disease and treatment) will be collected. We will report on any change in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival. In February 2021, the clinical trial registration was approved. Recruitment and data collection for the trial are ongoing (as of April 2023, 20 participants had already been randomized), and findings of this study are likely to be published late in 2024. This exercise training as a complementary treatment for patients with cancer is likely to promote positive effects on the health outcomes assessed, over and above any change in the CG, and prevent the reduction of initial cancer treatment dose prescribed. If these positive effects are shown, they will likely impact long-term outcomes such as hospitalizations and 12-month survival. Brazilian Clinical Trials Registry (ReBEC) RBR-5cyvzh9; https://ensaiosclinicos.gov.br/rg/RBR-5cyvzh9. PRR1-10.2196/43547.

Sections du résumé

BACKGROUND BACKGROUND
Lung or head and neck cancers are known for their high prevalence and mortality rates. Chemotherapy and radiotherapy are usually recommended as cancer treatment for these malignancies; however, they can negatively impact both the physical and mental status of patients. Hence, it is reasonable to consider resistance and aerobic exercise training to prevent these negative health outcomes. Further, several factors prevent patients from attending outpatient exercise training programs, and, therefore, a semisupervised home-based exercise training program may be seen as a well-accepted alternative.
OBJECTIVE OBJECTIVE
The aim of this study will be to investigate the effects of a semisupervised home-based exercise training program on physical performance, body composition, and self-reported outcomes; changes in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival in people with primary lung or head and neck cancer.
METHODS METHODS
Participants will be randomly allocated to the training group (TG) or control group (CG). The TG will undergo semisupervised home-based resistance and aerobic exercise training throughout their cancer treatment. The resistance training will be performed using elastic bands (TheraBand) twice a week. The aerobic training (ie, brisk walk) will be performed for at least 20 minutes per day outdoors. The equipment and tools used during the training sessions will be provided. This intervention will start the week before treatment commencement, will be performed throughout the duration of the treatment, and will continue for 2 weeks after treatment completion. The CG will undergo usual care (ie, cancer treatment with no formal exercise prescription). Assessments will take place 2 weeks before the beginning of the usual cancer treatment and 2 weeks after treatment completion. The measures of physical function (peripheral muscle strength, functional exercise capacity, and physical activity), body composition, and self-reported outcomes (symptoms of anxiety and depression, health-related quality of life, and symptoms related to the disease and treatment) will be collected. We will report on any change in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival.
RESULTS RESULTS
In February 2021, the clinical trial registration was approved. Recruitment and data collection for the trial are ongoing (as of April 2023, 20 participants had already been randomized), and findings of this study are likely to be published late in 2024.
CONCLUSIONS CONCLUSIONS
This exercise training as a complementary treatment for patients with cancer is likely to promote positive effects on the health outcomes assessed, over and above any change in the CG, and prevent the reduction of initial cancer treatment dose prescribed. If these positive effects are shown, they will likely impact long-term outcomes such as hospitalizations and 12-month survival.
TRIAL REGISTRATION BACKGROUND
Brazilian Clinical Trials Registry (ReBEC) RBR-5cyvzh9; https://ensaiosclinicos.gov.br/rg/RBR-5cyvzh9.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
PRR1-10.2196/43547.

Identifiants

pubmed: 37223986
pii: v12i1e43547
doi: 10.2196/43547
pmc: PMC10248778
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e43547

Informations de copyright

©Isis Grigoletto, Vinicius Cavalheri, Luis Alberto Gobbo, Karina Pozo, Enio Rodrigues Maia Filho, Diogo Gonçalves Ribeiro, Nara Ielo, Fabiano Francisco De Lima, Ercy Mara Cipulo Ramos. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 24.05.2023.

Références

Pulmonology. 2018 Nov - Dec;24(6):354-357
pubmed: 30554670
Curr Sports Med Rep. 2009 Jul-Aug;8(4):176-81
pubmed: 19584603
Eur J Cancer. 1994;30A(9):1326-36
pubmed: 7999421
BMC Cardiovasc Disord. 2011 Feb 01;11:7
pubmed: 21284837
Qual Life Res. 2007 Aug;16(6):1019-28
pubmed: 17479356
Cancer Nurs. 2012 Jan-Feb;35(1):48-54
pubmed: 21558852
Thorax. 2019 Aug;74(8):787-796
pubmed: 31048509
Acta Oncol. 2011 Feb;50(2):307-13
pubmed: 21231792
J Pain Symptom Manage. 2018 May;55(5):1364-1381.e5
pubmed: 29309818
Eur Respir J. 2014 Dec;44(6):1428-46
pubmed: 25359355
J Thorac Oncol. 2015 Jun;10(6):861-71
pubmed: 25831230
Med Sci Sports Exerc. 2014 Apr;46(4):656-63
pubmed: 24042307
Support Care Cancer. 2012 Aug;20(8):1709-17
pubmed: 21947412
J Pain Symptom Manage. 2013 May;45(5):811-21
pubmed: 23017624
Nature. 2019 Mar;567(7748):305-307
pubmed: 30894741
Clin Oncol (R Coll Radiol). 2010 Apr;22(3):208-21
pubmed: 20110159
Curr Oncol Rep. 2018 Mar 10;20(3):27
pubmed: 29525828
Clin Chem. 2008 Nov;54(11):1770-9
pubmed: 18801934
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Clin Rehabil. 2014 Nov;28(11):1096-106
pubmed: 24647863
Arch Phys Med Rehabil. 2018 Dec;99(12):2595-2620
pubmed: 29738745
Support Care Cancer. 2018 Apr;26(4):1289-1295
pubmed: 29090387
Head Neck. 2020 Jun;42(6):1218-1226
pubmed: 32343013
Curr Opin Support Palliat Care. 2017 Sep;11(3):247-257
pubmed: 28562375
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):664-672
pubmed: 29766660
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur Respir J. 2017 Mar 2;49(3):
pubmed: 28254766
Zhonghua Jie He He Hu Xi Za Zhi. 2007 Jan;30(1):27-30
pubmed: 17326969
J Physiother. 2016 Apr;62(2):60-7
pubmed: 26992323
Support Care Cancer. 2014 Jan;22(1):95-101
pubmed: 23995813
Braz J Phys Ther. 2013 Nov-Dec;17(6):556-63
pubmed: 24271092
BMC Cancer. 2012 Dec 05;12:572
pubmed: 23216897
J Clin Oncol. 2015 Jun 10;33(17):1918-27
pubmed: 25918291
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Support Care Cancer. 2017 Jun;25(6):1749-1758
pubmed: 28102437
Public Health Nutr. 2006 Sep;9(6):755-62
pubmed: 16925881
J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39
pubmed: 26285247
Scand J Med Sci Sports. 2012 Dec;22(6):804-15
pubmed: 21599754
Oncologist. 2007;12 Suppl 1:4-10
pubmed: 17573451
Med Sci Sports Exerc. 2007 Aug;39(8):1423-34
pubmed: 17762377
Braz J Phys Ther. 2017 Jan - Feb;21(1):58-68
pubmed: 28442076
Physiother Theory Pract. 2022 Jan;38(1):14-27
pubmed: 31975638

Auteurs

Isis Grigoletto (I)

Department of Physiotherapy, Faculty of Science and Technology, São Paulo State University, Presidente Prudente, São Paulo, Brazil.
Cancer Hospital of Presidente Prudente, Presidente Prudente, São Paulo, Brazil.

Vinicius Cavalheri (V)

Curtin School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia.
Curtin enAble Institute, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia.
Allied Health, South Metropolitan Health Service, Perth, Western Australia, Australia.

Luis Alberto Gobbo (LA)

Department of Physical Education, Faculty of Science and Technology, São Paulo State University, Presidente Prudente, São Paulo, Brazil.

Karina Pozo (K)

Department of Physiotherapy, Faculty of Science and Technology, São Paulo State University, Presidente Prudente, São Paulo, Brazil.
Cancer Hospital of Presidente Prudente, Presidente Prudente, São Paulo, Brazil.

Enio Rodrigues Maia Filho (ER)

Cancer Hospital of Presidente Prudente, Presidente Prudente, São Paulo, Brazil.

Diogo Gonçalves Ribeiro (DG)

Cancer Hospital of Presidente Prudente, Presidente Prudente, São Paulo, Brazil.

Nara Ielo (N)

Cancer Hospital of Presidente Prudente, Presidente Prudente, São Paulo, Brazil.
São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo, Brazil.

Fabiano Francisco De Lima (FF)

Department of Physiotherapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, Brazil.

Ercy Mara Cipulo Ramos (EMC)

Department of Physiotherapy, Faculty of Science and Technology, São Paulo State University, Presidente Prudente, São Paulo, Brazil.
Cancer Hospital of Presidente Prudente, Presidente Prudente, São Paulo, Brazil.

Classifications MeSH